Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Lexicon Pharmaceuticals Inc. | Pilavapadin (LX9211) - (PROGRESS) | Diabetic Peripheral Neuropathic Pain (DPNP) | Phase 2b | Data Released | Oral | Neurology |
| Lexicon Pharmaceuticals Inc. | LX9211 - (RELIEF-PHN 1) | Post-herpetic neuralgia | Phase 2 | Data Released | oral | Neurology |
| Lexicon Pharmaceuticals Inc. | LX9211 - (RELIEF-DPN 1) | Diabetic Peripheral Neuropathy | Phase 2 | Data Released | Oral | Neurology |
| LianBio | NBTXR3 with Cetuximab - (NANORAY-312) | Head and Neck Cancer | Phase 3 | Ongoing | Intratumoral | Oncology |
| LianBio | LYR-210 - (ENLIGHTEN I) | Chronic rhinosinusitis | Phase 3 | Trial Discontinued | Intranasal | Respiratory |
| LianBio | Mavacamten - (EXPLORER-CN) | Obstructive hypertrophic cardiomyopathy (oHCM) | Phase 3 | Oral | Cardiology | |
| LianBio | TP-03 - (LIBRA) | Demodex blepharitis | Phase 3 | Topical | Opthalmic | |
| LianBio | Sisunatovir | Respiratory syncytial virus (RSV) | Phase 2 | Oral | Respiratory |
